Taltz V Humira for psoriatic arthritis head to head

[Fred]

Lilly syas Taltz demonstrated superiority in improving active psoriatic arthritis compared to Humira.

Quote:

---

Eli Lilly announced today Taltz (ixekizumab) met the primary and all major secondary endpoints in the Phase 3b/4 SPIRIT-H2H study, which evaluated the efficacy and safety of Taltz versus Humira® (adalimumab) in patients with active psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drug (DMARD)-naive. The SPIRIT-H2H trial is the first completed large head-to-head (H2H) superiority study in active PsA. This open-label, randomized, controlled trial is the first and only H2H study that utilizes on-label dosing for both Taltz and Humira and includes concomitant conventional DMARDs.

At 24 weeks, patients treated with Taltz met the primary endpoint by demonstrating superiority in improving the signs and symptoms of active PsA compared to Humira as measured by the proportion of patients simultaneously achieving at least a 50-percent reduction in disease activity, as defined by the American College of Rheumatology (ACR50), as well as complete skin clearance as measured by the Psoriasis Area and Severity Index (PASI100). In addition, Taltz met the major secondary endpoints.

"The positive results from the SPIRIT-H2H trial reinforce that Taltz effectively treats the debilitating joint signs and symptoms of active psoriatic arthritis, while also providing skin clearance," said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. "These results provide evidence that Taltz can be used as a first-line biologic treatment for patients with active psoriatic arthritis."

A total of 566 active PsA patients were enrolled in the study to evaluate the efficacy and safety of Taltz compared to Humira. Patients with active PsA were randomized to receive Taltz at the approved dose (160-mg starting dose followed by 80 mg every four weeks), or Humira (40 mg every two weeks) for a total of 52 weeks, with the primary analysis conducted at 24 weeks. Patients meeting criteria for moderate-to-severe plaque psoriasis received the approved dose of Taltz (160-mg starting dose followed by 80 mg every two weeks from Week 2 to Week 12 and every four weeks thereafter) or Humira (80-mg starting dose followed by 40 mg every two weeks, one week after the initial dose).

"In the SPIRIT-H2H trial, Taltz demonstrated superiority in improving active psoriatic arthritis compared to Humira," said Philip Mease, M.D., Swedish Medical Center/Providence St. Joseph Health and University of Washington. "This study will help raise awareness and better inform conversations between patients and their healthcare providers about treatment options for active psoriatic arthritis."    

In SPIRIT-H2H, the safety profile of Taltz was consistent with previously reported results. No new safety signals were detected.

Lilly plans to submit detailed data from the SPIRIT-H2H study for disclosure at scientific meetings and in peer-reviewed journals in 2019.

Source: lilly.com

Humira (adalimumab)

Taltz (ixekizumab)

[Caroline]

Yeah, But now Humira has gone cheap, so there is a big chance that it will be prescribed earlier than Taltz

[Fred]

Yeah, But now Humira has gone cheap, so there is a big chance that it will be prescribed earlier than Taltz

I suppose that depends who is getting it cheaper and if the health care in ones country cares about their people.

[jiml]

Yeah, But now Humira has gone cheap, so there is a big chance that it will be prescribed earlier than Taltz

I suppose that depends who is getting it cheaper and if the health care in ones country cares about their people.

I think it's all about money in most countries that's why they try the cheapest first generally knowing it's going to have little or no effect and work their way up through to the most expensive last
Most health services have budgets and I'm sure a lot of them think a skin rash is not worthy expensive treatment

[Caroline]

Yeah, But now Humira has gone cheap, so there is a big chance that it will be prescribed earlier than Taltz

I suppose that depends who is getting it cheaper and if the health care in ones country cares about their people.

Well over here in the Netherlands Humira went down 80% in price, from €600 to €100 per injection. Because it went out of patent. So Abbvie lowered the price to block the road of the biosimilars.
That is quite a bonus for the ones who prescribe it and for the insurance. (After they have paid lots of money for years).

[Fred]

Yeah, But now Humira has gone cheap, so there is a big chance that it will be prescribed earlier than Taltz

I suppose that depends who is getting it cheaper and if the health care in ones country cares about their people.

I think it's all about money in most countries that's why they try the cheapest first generally knowing it's going to have little or no effect and work their way up through to the most expensive last
Most health services have budgets and I'm sure a lot of them think a skin rash is not worthy expensive treatment

They don't push Humira here much these days.

Humira €755
Taltz: €979

[Kat]

United States cost:

Humira $4846.00

Taltz $5134.00

Not really a huge difference in costs, considering they are both expensive. Oddly enough Cosentyx is listed at $4687.00 which is cheaper than both of them.

Stelara is listed at over $20,000.00 (and even more than that on my insurance explanation of benefits page!)

Sorry not trying to take this off topic, just comparing price with some other popular ones.

[Fred]

United States cost:

Humira  $4846.00

Taltz  $5134.00

Not really a huge difference in costs, considering they are both expensive.  Oddly enough Cosentyx is listed at $4687.00 which is cheaper than both of them.

Stelara is listed at over $20,000.00 (and even more than that on my insurance explanation of benefits page!)

Sorry not trying to take this off topic, just comparing price with some other popular ones.

That's interesting and like I said it depends who is getting it cheaper.